Cytek Biosciences (CTKB) AI Stock Analysis

• Market Cap: $607.36M
• Dividend Yield: N/A
• Average Volume (3M): 829.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: -2.18%
• EPS Growth: -30.96%
• Country: US
• Employees: 663
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): <0.01
• Shares Outstanding: 127,864,830
• 10 Day Avg. Volume: 1,085,737
• 30 Day Avg. Volume: 829,027
• PEG Ratio: 2.89
• Price to Book (P/B): 2.14
• Price to Sales (P/S): 4.23
• P/FCF Ratio: 38.79
• Enterprise Value/Market Cap: 0.36
• Enterprise Value/Revenue: 1.10
• Enterprise Value/Gross Profit: 2.05
• Enterprise Value/Ebitda: -11.91
• 1Y Price Target: $5.75
• Price Target Upside: 20.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.12
• Revenue Forecast (FY): $196.11M

• Rating: 52 Neutral
• Price Target: $4.50 ▼(-6.05% Downside)

The overall stock score of 52 reflects strong technical indicators and revenue growth, offset by weak profitability and valuation metrics. The company's stable balance sheet is a positive, but cash flow challenges and a negative P/E ratio are significant concerns.

Positive Factors

Market Leadership

Cytek's established brand and technology demonstrate market leadership, positioning the company for sustained growth and competitive advantage.

Recurring Revenue Growth

Strong growth in recurring revenue from services enhances revenue stability and predictability, supporting long-term financial health.

Product Innovation

The successful launch of the Aurora Evo Analyzer underscores Cytek's commitment to innovation, strengthening its product portfolio and market position.

Negative Factors

Declining Revenue Growth

Significant decline in revenue growth indicates challenges in market expansion and competitiveness, potentially impacting long-term sustainability.

Profitability Issues

Ongoing net losses highlight profitability challenges, which could constrain investment in growth initiatives and affect financial stability.

Increased Operating Expenses

Rising operating expenses, including legal costs, may strain margins and limit the company's ability to invest in strategic growth opportunities.

Cytek Biosciences Business Overview & Revenue Model

Company Description

Cytek Biosciences (CTKB) is a biotechnology company that specializes in providing advanced flow cytometry solutions for researchers and clinicians in the life sciences sector. The company focuses on developing innovative products that enhance the capabilities of flow cytometry, enabling more precise and efficient cellular analysis. Key offerings include its Aurora and Northern Lights product lines, which are designed for multi-parameter analysis of cells, as well as software solutions that facilitate data analysis and interpretation.

How the Company Makes Money

Cytek Biosciences generates revenue primarily through the sale of its flow cytometry instruments, reagents, and related consumables. The company’s revenue model is based on a combination of product sales and recurring revenue from consumables and service contracts. Key revenue streams include direct sales of the Aurora and Northern Lights systems, which are marketed to research institutions, clinical laboratories, and pharmaceutical companies. Additionally, Cytek benefits from partnerships with other biotech and pharmaceutical firms that may involve joint development initiatives or co-marketing agreements, further enhancing its market reach and revenue potential.

Cytek Biosciences Financial Statement Overview

Summary

Cytek Biosciences shows strong revenue growth but struggles with profitability and cash flow management. The balance sheet is stable with low leverage, but negative return on equity and cash flow challenges highlight areas for improvement.

Income Statement

Cytek Biosciences shows a mixed performance in its income statement. The company has experienced a significant revenue growth rate of 40.5% in the TTM period, indicating strong top-line expansion. However, profitability metrics such as the net profit margin and EBIT margin are negative, reflecting ongoing challenges in achieving operational efficiency. The gross profit margin remains healthy at 54.4%, but the negative EBITDA margin suggests difficulties in covering operating expenses.

Balance Sheet

The balance sheet of Cytek Biosciences is relatively stable. The debt-to-equity ratio is low at 0.037, indicating conservative leverage and a strong equity position. However, the return on equity is negative, suggesting that the company is not generating sufficient returns on its equity base. The equity ratio is robust, reflecting a solid capital structure with a high proportion of equity financing.

Cash Flow

Cytek Biosciences faces challenges in its cash flow management. The free cash flow growth rate is negative, and the operating cash flow is also negative in the TTM period, indicating cash flow constraints. The free cash flow to net income ratio is relatively high, suggesting that the company is managing to convert a significant portion of its net income into free cash flow, but the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	196.83M	200.45M	193.01M	164.04M	127.95M	92.84M
Gross Profit	105.23M	111.11M	109.43M	100.97M	79.14M	51.71M
EBITDA	-18.13M	-10.03M	-4.41M	9.49M	8.92M	15.37M
Net Income	-12.82M	-6.02M	-12.15M	2.58M	3.00M	19.41M
Balance Sheet
Total Assets	494.92M	499.50M	494.46M	519.48M	463.31M	219.98M
Cash, Cash Equivalents and Short-Term Investments	261.73M	277.86M	262.41M	341.15M	364.62M	165.23M
Total Debt	35.16M	17.02M	14.14M	18.09M	0.00	2.77M
Total Liabilities	116.35M	103.76M	101.39M	93.93M	57.92M	236.01M
Stockholders Equity	378.57M	395.74M	393.06M	425.30M	405.04M	-16.03M
Cash Flow
Free Cash Flow	-5.90M	21.85M	454.00K	-22.10M	266.00K	13.61M
Operating Cash Flow	-1.92M	25.38M	5.28M	-12.23M	4.63M	15.16M
Investing Cash Flow	-51.47M	-82.97M	-93.89M	-55.91M	-20.99M	-1.55M
Financing Cash Flow	-15.85M	-15.82M	-41.81M	5.51M	213.56M	122.61M

Cytek Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTKB, the sentiment is Positive. The current price of 4.79 is above the 20-day moving average (MA) of 4.17, above the 50-day MA of 3.96, and above the 200-day MA of 3.90, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 70.96 is Negative, neither overbought nor oversold. The STOCH value of 83.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTKB.

Cytek Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	66 Neutral	$624.23M	-1,020.27	4.97%	―	1.58%	―
SIBN	57 Neutral	$680.33M	―	-12.91%	―	23.27%	43.90%
BFLY	57 Neutral	$661.82M	-7.83	-41.42%	―	16.04%	28.91%
CTKB	52 Neutral	$607.36M	―	-3.36%	―	-2.18%	-30.96%
VREX	52 Neutral	$489.70M	-3.64	-25.57%	―	-1.36%	-479.49%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PACB	45 Neutral	$531.36M	―	-205.41%	―	-10.72%	-16.00%

Cytek Biosciences Corporate Events

Cytek Biosciences Earnings Call: Mixed Sentiment and Growth

The recent earnings call of Cytek Biosciences, Inc. presented a mixed sentiment, reflecting both achievements and challenges. The company reported significant revenue growth in the Asia Pacific (APAC) region and in its service and reagent sectors. However, these positive developments were counterbalanced by difficulties in the EMEA region and the U.S. academic and government sectors. Additionally, increased operating expenses and a net loss contributed to the overall balanced sentiment of the call.

Cytek Biosciences Reports Modest Revenue Growth in Q3 2025

Cytek Biosciences, Inc., a leading cell analysis solutions company, specializes in advancing next-generation cell analysis tools using its patented Full Spectrum Profiling technology. The company operates primarily in the biotechnology sector and offers a comprehensive suite of products and services for research use.

Cytek Biosciences Earnings Call Reveals Mixed Outlook

The recent earnings call for Cytek Biosciences, Inc. painted a mixed picture for the company. On one hand, there was notable growth in recurring revenue and the U.S. market, alongside the successful launch of new products and an expanding Cytek Cloud user base. On the other hand, challenges in the EMEA and APAC regions, a decline in overall revenue, and lowered full-year guidance underscore ongoing difficulties. This combination of factors results in a balanced outlook for Cytek.

Cytek Biosciences: Q2 2025 Financial Performance Overview

Cytek Biosciences, Inc., headquartered in Fremont, California, is a leading company in the cell analysis solutions sector, known for its Full Spectrum Profiling technology that enhances cell analysis through high-resolution and high-sensitivity tools.